Expression of PAX3 in Ewing's sarcoma family of tumors

Biochemical and Molecular Medicine

Volumn 60, Issue 2, 1997, Pages 121-126

  Schulte, Theodor W ^b   Toretsky, Jeffrey A ^a   Ress, Elisabeth ^a   Helman, Lee ^a   Neckers, Leonard M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Clinical Pharmacology Branch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; RNA;

ARTICLE; CHROMOSOME TRANSLOCATION 11; CONTROLLED STUDY; EWING SARCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROECTODERM TUMOR; PROTEIN EXPRESSION; TUMOR CELL LINE;

EID: 0031127217     PISSN: 10773150     EISSN: None     Source Type: Journal    
DOI: 10.1006/bmme.1997.2567     Document Type: Article

References (38)

1. Horowitz M E, Malawer M M, DeLaney T F, Tsokos M G. Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. Principles and Practice of Pediatric Oncology. 1993;J. B. Lippincott, Philadelphia. p. 795-821.
2. Turc C C, Aurias A, Mugneret F, Lizard S, Sidaner I, Volk C, Thiery J P, Olschwang S, Philip I, Berger M P. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11; 22)(q24; q12). Cancer Genet Cytogenet. 32:1988;229-238.
3. Whang P J, Triche T J, Knutsen T, Miser J, Douglass E C, Israel M A. Chromosome translocation in peripheral neuroepithelioma. N Engl J Med. 311:1984;584-585.
4. Lipinski M, Braham K, Philip I, Wiels J, Philip T, Goridis C, Lenoir G M, Tursz T. Neuroectoderm-associated antigens on Ewing's sarcoma cell lines. Cancer Res. 47:1987;183-187.
5. Mujoo K, Cheresh D A, Yang H M, Reisfeld R A. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 47:1987;1098-1104.
6. Cavazzana A O, Miser J S, Jefferson J, Triche T J. Experimental evidence for a neural origin of Ewing's sarcoma of bone. Am J Pathol. 127:1987;507-518.
7. Thiele C J, McKeon C, Triche T J, Ross R A, Reynolds C P, Israel M A. Differential protooncogene expression characterizes histopathologically indistinguishable tumors of the peripheral nervous system. J Clin Invest. 80:1987;804-811.
8. McKeon C, Thiele C J, Ross R A, Kwan M, Triche T J, Miser J S, Israel M A. Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma. Cancer Res. 48:1988;4307-4311.
9. Frigerio G, Burri M, Bopp D, Baumgartner S, Noll M. Structure of the segmentation gene paired and the Drosophila PRD gene set as part of a gene network. Cell. 47:1986;735-746.
10. Toretsky J A, Neckers L, Wexler L H. Detection of (11; 22)(q24; q12) translocation-bearing cells in peripheral blood progenitor cells of patients with Ewing's sarcoma family of tumors. J Natl Cancer Inst. 87:1995;385-386.
11. Whang P J, Triche T J, Knutsen T, Miser J, Kao S S, Tsai S, Israel M A. Cytogenetic characterization of selected small round cell tumors of childhood. Cancer Genet Cytogenet. 21:1986;185-208.
12. Rosolen A, Whitesell L, Ikegaki N, Kennett R, Neckers L M. Antisense inhibition of N-myc reduces cell growth but does not affect c-myc expression in the neuroepithelioma cell line CHP100. Prog Clin Biol Res. 366:1991;29-36.
13. Schulte T W, Blagosklonny M V, Ingui C, Neckers L. Disruption of the Raf-1-hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem. 270:1995;24585-24588.
14. Sublett J E, Jeon I S, Shapiro D N. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator. Oncogene. 11:1995;545-552.
15. Chavany C, Mimnaugh E, Miller P, Bitton R, Nguyen P, Trepel J, Whitesell L, Schnur R, Moyer J, Neckers L. p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem. 271:1996;4974-4977.
16. Loizaga J M. What's new in Ewing's tumor? Pathol Res Pract. 189:1993;616-620.
17. Goulding M D, Chalepakis G, Deutsch U, Erselius J R, Gruss P. Pax-3, a novel murine DNA binding protein expressed during early neurogenesis. EMBO J. 10:1991;1135-1147.
18. Chalepakis G, Goulding M, Read A, Strachan T, Gruss P. Molecular basis of splotch and Waardenburg Pax-3 mutations. Proc Natl Acad Sci USA. 91:1994;3685-3689.
19. Pruitt S C. Expression of Pax-3- and neuroectoderm-inducing activities during differentiation of P19 embryonal carcinoma cells. Development. 116:1992;573-583.
20. Pruitt S C. Discrete endogenous signals mediate neural competence and induction in P19 embryonal carcinoma stem cells. Development. 120:1994;3301-3312.
21. Dressler G R, Douglass E C. Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor. Proc Natl Acad Sci USA. 89:1992;1179-1183.
22. Gnarra J R, Dressler G R. Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. Cancer Res. 55:1995;4092-4098.
23. Eccles M R, Yun K, Reeve A E, Fidler A E. Comparative in situ hybridization analysis of PAX2, PAX8, and WT1 gene transcription in human fetal kidney and Wilms' tumors. Am J Pathol. 146:1995;40-45.
24. Tremblay P, Gruss P. Pax: Genes for mice and men. Pharmacol Ther. 61:1994;205-226.
25. Stoykova A, Gruss P. Roles of Pax-genes in developing and adult brain as suggested by expression patterns. J Neurosci. 14:1994;1395-1412.
26. Poleev A, Wendler F, Fickenscher H, Zannini M S, Yaginuma K, Abbott C, Plachov D. Distinct functional properties of three human paired-box-protein, PAX8, isoforms generated by alternative splicing in thyroid, kidney and Wilms' tumors. Eur J Biochem. 228:1995;899-911.
27. Kozmik Z, Sure U, Ruedi D, Busslinger M, Aguzzi A. Deregulated expression of PAX5 in medulloblastoma. Proc Natl Acad Sci USA. 92:1995;5709-5713.
28. Stuart E T, Kioussi C, Aguzzi A, Gruss P. PAX5 Expression Correlates with Increasing malignancy in human astrocytomas. Clin Cancer Res. 1:1995;207-214.
29. Fabbro D, Di L C, Beltrami C A, Belfiore A, Di L R, Damante G. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res. 54:1994;4744-4749.
30. Galili N, Davis R J, Fredericks W J, Mukhopadhyay S, Rauscher F3, Emanuel B S, Rovera G, Barr F G. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 5:1993;230-235.
31. Shapiro D N, Sublett J E, Li B, Downing J R, Naeve C W. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res. 53:1993;5108-5112.
32. Davis R J, D'Cruz C M, Lovell M A, Biegel J A, Barr F G. Fusion of PAX7 to FKHR by the variant t(1; 13)(p36; q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 54:1994;2869-2872.
33. Dressler G R. Pax-2, kidney development, and oncogenesis. Med Pediatr Oncol. 27:1996;440-444.
34. Stuart E T, Haffner R, Oren M, Gruss P. Loss of p53 function through PAX-mediated transcriptional repression. EMBO J. 14:1995;5638-5645.
35. Epstein J A, Lam P, Jepeal L, Maas R L, Shapiro D N. Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem. 270:1995;11719-11722.
36. Maulbecker C C, Gruss P. The oncogenic potential of Pax genes. EMBO J. 12:1993;2361-2367.
37. Stuart E T, Gruss P. PAX genes: What's new in developmental biology and cancer? Hum Mol Genet. 4:1995;1717-1720.
38. Stuart E T, Gruss P. PAX: Developmental control genes in cell growth and differentiation. Cell Growth Differ. 7:1996;405-412.